Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare between the addition of Mg sulphate or Nalbuphine to intraperitoneal bupivacaine installation in laparoscopic hysterectomy for postoperative pain control and their relative adverse effects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group BM | Active Comparator | bupivacaine 0.25% plus magnesium sulphate. |
|
| Group BN | Active Comparator | bupivacaine 0.25% plus nalbuphine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bupivacaine 0.25% | Drug | Patients will receive 30 mL of intraperitoneal bupivacaine 0.25% |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rescue analgesia time | Time to first analgesia requirment(considering the extubation is the zero time) | First 24 hours postoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| Visual analogue scale [VAS] | Visual analogue scale [VAS] will be used to measure pain score at 30 min, 1, 2, 4, 6, 8, 10, 12 and 24 h after surgery. All the study patients will be instructed about the use of the VAS scale before induction of anesthesia (VAS score 0 cm = no pain, VAS score 10 cm = worst possible pain) | First 24 hours postoperatively |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Marwa Elbeialy | Cairo | 11591 | Egypt |
Not provided
| ID | Term |
|---|---|
| D008278 | Magnesium Sulfate |
| D009266 | Nalbuphine |
| D000701 | Analgesics, Opioid |
| ID | Term |
|---|---|
| D017616 | Magnesium Compounds |
| D007287 | Inorganic Chemicals |
| D013431 | Sulfates |
| D013464 | Sulfuric Acids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Magnesium sulphate. | Drug | Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate. |
|
| nalbuphine | Drug | Patients will receive intraperitoneal 5 mg nalbuphine |
|
|
| Total analgesic consumption | Intravenous diclofenac 75 mg will be given as rescue analgesic when VAS ≥ 4.Total diclofenac consumption will be recorded. | First 24 hours postoperatively |
| D013456 |
| Sulfur Acids |
| D013457 | Sulfur Compounds |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D009294 | Narcotics |
| D002492 | Central Nervous System Depressants |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D000700 | Analgesics |
| D018689 | Sensory System Agents |
| D018373 | Peripheral Nervous System Agents |
| D002491 | Central Nervous System Agents |
| D045506 | Therapeutic Uses |